IP Library Granted Patent US 11,788,074
Granted Patent B2
US 11,788,074 · App. 17/348,127 · Granted Oct 17, 2023

Vaccinia capping enzyme compositions and methods

Inventors: Saulius Vainauskas (Newburyport, MA); Siu-Hong Chan (Ipswich, MA); Christopher H. Taron (Essex, MA)
Assignee: New England Biolabs, Inc.
C12N9/1241C12N15/815C07K2319/00C12R2001/84C12Y207/0705
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,788,074
App. No.
17/348,127
Granted
Oct 17, 2023
Kind
B2
Abstract

The present disclosure relates, according to some embodiments, to compositions, methods, and/or kits for producing vaccinia capping enzyme. For example, active, heterodimers of vaccinia capping enzyme may be produced as fusions comprising D1 and D12 subunits. Vaccinia capping enzyme fusion proteins may further comprise a linker.

Claims (12)

1. A composition comprising a vaccinia capping enzyme fusion, wherein the vaccinia capping enzyme fusion comprises, in an N-terminal to C-terminal orientation:

(a) a D1 subunit;

(b) a linker; and

(c) a D12 subunit,

wherein the linker has at least 90% identity to SEQ ID NO: 3.

2. A composition according to claim 1 , wherein the D1 subunit has an amino acid sequence having at least 90% identity to positions 24 to 867 of SEQ ID NO: 1.

3. A composition according to claim 1 , wherein the D1 subunit has an amino acid sequence having at least 90% identity to SEQ ID NO: 1.

4. A composition according to claim 1 , wherein the D 12 subunit has an amino acid sequence having at least 90% identity to SEQ ID NO: 2.

5. A cell comprising the composition according to claim 1 .

6. A cell according to claim 5 , wherein the vaccinia capping enzyme fusion protein has an amino acid sequence at least 90% identical to SEQ ID NO: 4 or at least 90% identical to SEQ ID NO: 6 or at least 90% identical to SEQ ID NO: 8.

7. A cell according to claim 5 , wherein the cell is a Kluyveromyces lactis cell or a Pichia pastoris cell.

8. A vaccinia capping enzyme fusion, comprising in an N-terminal to C-terminal orientation: (a) a D1 subunit; (b) a linker; and (c) a D12 subunit, wherein the linker has ° at least 90% identity to SEQ ID NO: 3.

Assignments (2)
NOTICE OF GRANT OF SECURITY INTEREST IN PATENTS Recorded Sep 27, 2023
From: NEW ENGLAND BIOLABS, INC.
To: BANK OF AMERICA, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 065044/0729 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 23, 2021
From: VAINAUSKAS, SAULIUS; CHAN, SIU-HONG; TARON, CHRISTOPHER H.
To: NEW ENGLAND BIOLABS, INC.
Reel/Frame 056960/0996 →
Cited By (3)
US 12,312,610 US 12,398,173 US 12,479,880